stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Free cash flow margin
Harmony Biosciences Holdings, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 32.7%, down 7.4 percentage points from fiscal 2025 (40.1%). Over the past ten years it has ranged from −3,379.2% (fiscal 2019) to 40.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 40.1% | 9.47 |
| FY2024 | 30.6% | (7.05) |
| FY2023 | 37.6% | 13.82 |
| FY2022 | 23.8% | 24.39 |
| FY2021 | −0.57% | 2.55 |
| FY2020 | −3.12% | 3,376.11 |
| FY2019 | −3,379.2% | (3,379.23) |
| FY2018 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | 32.7% |
| SRPT Sarepta Therapeutics, Inc. compare | 9.02% |
| FTRE Fortrea Holdings Inc. compare | 6.41% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MAZE Maze Therapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| TRVI Trevi Therapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. compare | −46.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue